NCT03438435View on ClinicalTrials.gov

Fluorescence QRH-882260 Peptide Imaging in the Bile Duct

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 22, 2019

Primary Completion Date

August 21, 2020

Study Completion Date

August 21, 2020

Conditions
Cholangiocarcinoma
Interventions
DRUG

QRH-882260 Heptapeptide

Imaging agent

Trial Locations (1)

98195

University of Washington Medical Center, Seattle

All Listed Sponsors
collaborator

University of Washington

OTHER

lead

D. Kim Turgeon, MD

OTHER

NCT03438435 - Fluorescence QRH-882260 Peptide Imaging in the Bile Duct | Biotech Hunter | Biotech Hunter